

KTIN Therapeutics

First-in-Class Anti-Aging Platform | \$15M Series A


Columbia University Startup | Restoring Muscle, Metabolism & Mind

The Problem

Aging drives multi-system decline with **no disease-modifying treatments** available:

Circulating osteocalcin levels decrease early in life

Similar trend is seen in dogs, cats, pigs, cows and horses




7/31/20

Prepared by Martin Dueñas | martin@onixhub.com

30

treatments

- **Muscle:** 10-16% elderly have sarcopenia; 14M+ falls annually; 38,700+ deaths from falls (2021)
- **Metabolic:** 50% seniors have diabetes/pre-diabetes; obesity epidemic across age groups
- **Cognitive:** 15-20% experience cognitive decline
- **Market Impact:** \$60B+ addressable market with fragmented symptom-based



Our Solution: Osteocalcin (OCN) Anti-Aging Platform

Two Products, One Revolutionary Mechanism:

- **KTIN-100** (IM injection, 6-8 weeks): IL-6/ALN conjugate stimulates endogenous OCN
- **KTIN-200** (daily oral): Direct OCN delivery

Proven Preclinical Results:



- 30% better muscle endurance in mice
- Memory boost in aged mice via GPR158 pathway
- 5-10% lower fasting glucose levels
- Recovery from sarcopenia in cachexia mouse models

Only OCN can fully negate the deleterious effect of DEX on exercise

Note: dexamethasone induced sarcopenia is almost as severe as cachexia

— Vehicle
— DEX
- - - DEX + VK5211
— DEX + EPO
— DEX + OCN

■ Vehicle
■ DEX
□ DEX + VK5211
■ DEX + EPO
■ DEX + OCN
■ Vehicle + OCN



OCN outperforms EPO

Market Opportunity (\$60B+)

Indication	Market Size	Population
Falls/Sarcopenia	\$2-5B	10-16% elderly
Mild Cognitive Impairment	\$30B	15-20% seniors
Metabolic Dysfunction (T2D/Obesity)	\$28B	50% senior pre-diabetic
Rare Diseases	\$1-2B	LGMD, SMA (orphan pricing)

Competitive Advantage

- ✓ **First-Mover:** Only OCN-based aging therapy
- ✓ **World-Class Science:** Dr. Gerard Karsenty's 20+ years OCN research
- ✓ **Strong IP:** Columbia University PCT application
- ✓ **Natural Approach:** Physiological, safe aging solution

Development Timeline & Milestones

- **2025-2026:** CMC development, GLP studies, KTIN-200 optimization
- **2026:** FDA IND submission, orphan drug designations
- **2027:** Phase 1/1b trials (falls/sarcopenia)
- **2027-2028:** Animal health out-licensing (\$20-40M)

Financial Projections

- **Revenue by Year 7:** \$50-100M (aging) + \$20-30M (rare diseases)
- **Exit Strategy:** Pharma acquisition (Amgen, Novo Nordisk) or IPO (5-7 years)
- **Target ROI:** 10x on \$15M investment

Use of Funds (\$15M Series A)

- **\$5M** CMC Development (KTIN-100/200 manufacturing)
- **\$3M** GLP Studies (pre-IND animal studies)
- **\$5M** Phase 1 Human Trial (first-in-human safety)
- **\$1M** KTIN-200 development
- **\$1M** Operations & team expansion

Leadership Team

- **Martin Dueñas, MPA** - CEO & Co-Founder (10+ years biotech startups)
- **Dr. Gerard Karsenty, MD, PhD** - CSO & Scientific Founder (Columbia University, world-renowned OCN expert)

Strategic Partnerships

Universities: Columbia, Cornell, CIBERDEM Spain, INSERM

CROs: Altascienes, NorthEast Biolabs, Argenta

CDMOs: KBI, Catalent, Lonza, Piramal

Contact: Martin Dueñas, CEO | martin@onixhub.com

Investment Thesis

Why Invest Now:

- First-mover in \$60B+ aging market with rare disease upside
- Proven preclinical efficacy across multiple age-related conditions
- Clear regulatory pathway to Phase 1 trials
- World-class scientific foundation and IP protection
- Natural, transformative approach to extending healthspan

Contact: Martin Dueñas, CEO | martin@onixhub.com

"Redefining aging with KTIN-100 & KTIN-200 — extending healthspan and transforming lives"